## Matthias Guckenberger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5816027/publications.pdf Version: 2024-02-01

		10388	19188
486	19,335	72	118
papers	citations	h-index	g-index
537	537	537	15107
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology, 2020, 295, 328-338.	7.3	1,869
2	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncology, The, 2020, 21, e18-e28.	10.7	588
3	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.6	352
4	MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiation Oncology, 2019, 14, 92.	2.7	252
5	Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncológica, 2006, 45, 838-847.	1.8	250
6	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiotherapy and Oncology, 2017, 124, 11-17.	0.6	230
7	EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology, 2021, 32, 1332-1347.	1.2	227
8	Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiotherapy and Oncology, 2012, 102, 335-342.	0.6	209
9	A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy. Journal of Thoracic Oncology, 2012, 7, 1382-1393.	1.1	198
10	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Research, 2018, 78, 1031-1043.	0.9	193
11	Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes?. Radiotherapy and Oncology, 2009, 93, 259-265.	0.6	191
12	Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	1.1	189
13	Dose–Response Relationship for Image-Guided Stereotactic Body Radiotherapy of Pulmonary Tumors: Relevance of 4D Dose Calculation. International Journal of Radiation Oncology Biology Physics, 2009, 74, 47-54.	0.8	181
14	Definition of stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2014, 190, 26-33.	2.0	180
15	Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis. Journal of Thoracic Oncology, 2013, 8, 1050-1058.	1.1	179
16	Stereotactic radiosurgery for treatment of brain metastases. Strahlentherapie Und Onkologie, 2014, 190, 521-532.	2.0	179
17	kV Cone-Beam CT-Based IGRT. Strahlentherapie Und Onkologie, 2011, 187, 284-291.	2.0	177
18	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiotherapy and Oncology,	0.6	177

2017, 124, 1-10.

#	Article	IF	CITATIONS
19	Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncology, The, 2015, 16, e595-e603.	10.7	170
20	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treatment Reviews, 2017, 53, 25-37.	7.7	169
21	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
22	Radiotherapy in adrenocortical carcinoma. Cancer, 2009, 115, 2816-2823.	4.1	165
23	Internal mammary and medial supraclavicular lymph node chain irradiation in stage l–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1602-1610.	10.7	164
24	Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 921-928.	0.8	161
25	Magnitude and clinical relevance of translational and rotational patient setup errors: A cone-beam CT study. International Journal of Radiation Oncology Biology Physics, 2006, 65, 934-942.	0.8	156
26	Investigation of the usability of conebeam CT data sets for dose calculation. Radiation Oncology, 2008, 3, 42.	2.7	156
27	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.8	156
28	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncológica, 2018, 57, 1070-1074.	1.8	152
29	Dose–response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 65-70.	0.6	147
30	Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiation Oncology, 2014, 9, 226.	2.7	144
31	ICRU reportÂ91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlentherapie Und Onkologie, 2019, 195, 193-198.	2.0	143
32	Four-Dimensional Treatment Planning for Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 276-285.	0.8	142
33	Precision of Image-Guided Radiotherapy (IGRT) in Six Degrees of Freedom and Limitations in Clinical Practice. Strahlentherapie Und Onkologie, 2007, 183, 307-313.	2.0	133
34	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	1.2	132
35	Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): Results of a serial follow-up CT study. Radiotherapy and Oncology, 2007, 85, 435-442.	0.6	128
36	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group "stereotactic radiotherapy― Lung Cancer, 2016, 97, 51-58.	2.0	128

#	Article	IF	CITATIONS
37	Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy (IGRT) of pulmonary tumors. Radiotherapy and Oncology, 2007, 83, 57-64.	0.6	127
38	Dose–response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiotherapy and Oncology, 2014, 110, 499-504.	0.6	125
39	Positioning accuracy of cone-beam computed tomography in combination with a HexaPOD robot treatment table. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1220-1228.	0.8	124
40	Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncológica, 2017, 56, 1531-1536.	1.8	123
41	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	7.1	122
42	Modern therapeutic approaches for the treatment of malignant liverÂtumours. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 755-772.	17.8	120
43	Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiotherapy and Oncology, 2009, 91, 288-295.	0.6	119
44	Cone-beam CT based image-guidance for extracranial stereotactic radiotherapy of intrapulmonary tumors. Acta Oncológica, 2006, 45, 897-906.	1.8	117
45	Dose to heart substructures is associated with non-cancer death after SBRT in stage l–Il NSCLC patients. Radiotherapy and Oncology, 2017, 123, 370-375.	0.6	115
46	The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer, 2018, 18, 283.	2.6	115
47	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial. Lung Cancer, 2019, 133, 83-87.	2.0	113
48	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. British Journal of Radiology, 2018, 91, 20170498.	2.2	109
49	Is a Single Respiratory Correlated 4D-CT Study Sufficient for Evaluation of Breathing Motion?. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1352-1359.	0.8	108
50	Potential of Adaptive Radiotherapy to Escalate the Radiation Dose in Combined Radiochemotherapy for Locally Advanced Non–Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 901-908.	0.8	107
51	Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?. Journal of Thoracic Oncology, 2012, 7, 542-551.	1.1	105
52	Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 13-20.	0.6	103
53	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiotherapy and Oncology, 2016, 118, 485-491.	0.6	101
54	Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation. Journal of Neurosurgery: Spine, 2016, 24, 928-936.	1.7	100

#	Article	IF	CITATIONS
55	Stereotactic body radiotherapy for liver tumors. Strahlentherapie Und Onkologie, 2014, 190, 872-881.	2.0	99
56	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. Journal of Clinical Oncology, 2015, 33, 4158-4166.	1.6	99
57	LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. British Journal of Radiology, 2015, 88, 20150036.	2.2	96
58	Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlentherapie Und Onkologie, 2020, 196, 417-420.	2.0	96
59	Evaluation of an automated knowledge based treatment planning system for head and neck. Radiation Oncology, 2015, 10, 226.	2.7	94
60	Transcriptome Analysis of Neisseria meningitidis during Infection. Journal of Bacteriology, 2003, 185, 155-164.	2.2	93
61	Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation. Radiotherapy and Oncology, 2015, 116, 374-380.	0.6	92
62	Tumor tracking and motion compensation with an adaptive tumor tracking system (ATTS): System description and prototype testing. Medical Physics, 2008, 35, 3911-3921.	3.0	90
63	Post-radiochemotherapy PET radiomics in head and neck cancer – The influence of radiomics implementation on the reproducibility of local control tumor models. Radiotherapy and Oncology, 2017, 125, 385-391.	0.6	89
64	Accuracy and inter-observer variability of 3D versus 4D cone-beam CT based image-guidance in SBRT for lung tumors. Radiation Oncology, 2012, 7, 81.	2.7	88
65	Dosimetric consequences of translational and rotational errors in frame-less image-guided radiosurgery. Radiation Oncology, 2012, 7, 63.	2.7	88
66	Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey. Journal of Neurosurgery: Spine, 2017, 26, 299-306.	1.7	88
67	Stereotactic body radiotherapy for oligo-metastatic liver disease – Influence of pre-treatment chemotherapy and histology on local tumor control. Radiotherapy and Oncology, 2017, 123, 227-233.	0.6	85
68	Intensity-Modulated Radiotherapy (IMRT) of Localized Prostate Cancer. Strahlentherapie Und Onkologie, 2007, 183, 57-62.	2.0	84
69	Image-Guided Radiotherapy for Liver Cancer Using Respiratory-Correlated Computed Tomography and Cone-Beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2008, 71, 297-304.	0.8	83
70	A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking. Radiotherapy and Oncology, 2016, 119, 159-165.	0.6	82
71	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Journal of Thoracic Oncology. 2021. 16. 278-288.	1.1	82
72	Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiotherapy and Oncology, 2010, 94, 53-59.	0.6	78

#	Article	IF	CITATIONS
73	A multi-institution evaluation of deformable image registration algorithms for automatic organ delineation in adaptive head and neck radiotherapy. Radiation Oncology, 2012, 7, 90.	2.7	78
74	Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis. Journal of Neurosurgery: Spine, 2016, 25, 646-653.	1.7	72
75	Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 20-30.	6.4	72
76	Precision required for dose-escalated treatment of spinal metastases and implications for image-guided radiation therapy (IGRT). Radiotherapy and Oncology, 2007, 84, 56-63.	0.6	71
77	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	7.0	70
78	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1449-1461.	1.2	69
79	Feasibility Study for Markerless Tracking of Lung Tumors in Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 618-627.	0.8	68
80	The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer, 2019, 19, 173.	2.6	68
81	Stereotactic body radiation therapy in the re-irradiation situation – a review. Radiation Oncology, 2013, 8, 7.	2.7	66
82	Reliability of the Bony Anatomy in Image-Guided Stereotactic Radiotherapy of Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2007, 69, 294-301.	0.8	65
83	Adaptive Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Does Not Underdose the Microscopic Disease and has the Potential to Increase Tumor Control. International Journal of Radiation Oncology Biology Physics, 2011, 81, e275-e282.	0.8	65
84	PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer, 2020, 20, 406.	2.6	64
85	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. European Urology, 2021, 80, 306-315.	1.9	64
86	Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments. Journal of Thoracic Oncology, 2014, 9, 1598-1608.	1.1	63
87	Image guidance in radiation therapy for better cure of cancer. Molecular Oncology, 2020, 14, 1470-1491.	4.6	63
88	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 2019, 30, 161-165.	1.2	60
89	Technologyâ€driven research for radiotherapy innovation. Molecular Oncology, 2020, 14, 1500-1513.	4.6	60
90	Nonrigid Patient Setup Errors in the Head-and-Neck Region. Strahlentherapie Und Onkologie, 2007, 183, 506-511.	2.0	59

#	Article	IF	CITATIONS
91	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. Radiotherapy and Oncology, 2020, 152, 203-207.	0.6	59
92	Toxicity after Intensity-Modulated, Image-Guided Radiotherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 535-543.	2.0	58
93	CT radiomics and PET radiomics: ready for clinical implementation?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 355-370.	0.7	58
94	Modeling Local Control After Hypofractionated Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Report From the Elekta Collaborative Lung Research Group. International Journal of Radiation Oncology Biology Physics, 2012, 84, e379-e384.	0.8	57
95	Lack of a Dose-Effect Relationship for Pulmonary Function Changes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1074-1081.	0.8	57
96	Hypofractionated radiotherapy for prostate cancer. Radiation Oncology, 2014, 9, 275.	2.7	56
97	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiotherapy and Oncology, 2017, 123, 182-188.	0.6	55
98	Support Vector Machine-Based Prediction of Local Tumor Control After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 732-738.	0.8	54
99	Stereotactic body radiotherapy for centrally located stageÂl NSCLC. Strahlentherapie Und Onkologie, 2015, 191, 125-132.	2.0	52
100	Respiratory motion-management in stereotactic body radiation therapy for lung cancer – A dosimetric comparison in an anthropomorphic lung phantom (LuCa). Radiotherapy and Oncology, 2016, 121, 328-334.	0.6	52
101	Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer. Strahlentherapie Und Onkologie, 2008, 184, 668-673.	2.0	51
102	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. Acta Oncológica, 2019, 58, 1275-1282.	1.8	50
103	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiation Oncology, 2020, 15, 74.	2.7	50
104	SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer, 2017, 106, 50-57.	2.0	49
105	Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2201-2217.	6.4	47
106	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. International Journal of Radiation Oncology Biology Physics, 2020, 108, 379-389.	0.8	47
107	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	3.3	46
108	ITV, mid-ventilation, gating or couch tracking – A comparison of respiratory motion-management techniques based on 4D dose calculations. Radiotherapy and Oncology, 2017, 124, 80-88.	0.6	45

#	Article	IF	CITATIONS
109	Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature. Cancer Treatment Reviews, 2019, 80, 101892.	7.7	45
110	Late small bowel toxicity after adjuvant treatment for rectal cancer. International Journal of Colorectal Disease, 2006, 21, 209-220.	2.2	44
111	Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiation Oncology, 2018, 13, 102.	2.7	44
112	Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiotherapy and Oncology, 2019, 132, 42-47.	0.6	44
113	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 889-900.	6.4	44
114	Feasibility and Usability Aspects of Continuous Remote Monitoring of Health Status in Palliative Cancer Patients Using Wearables. Oncology, 2020, 98, 386-395.	1.9	44
115	Planning benchmark study for SBRT of early stage NSCLC. Strahlentherapie Und Onkologie, 2017, 193, 780-790.	2.0	44
116	Transcriptome-based antigen identification for Neisseria meningitidis. Vaccine, 2003, 21, 768-775.	3.8	43
117	33, 1275-1280.	3.0	43
118	Clinical practice of image-guided spine radiosurgery - results from an international research consortium. Radiation Oncology, 2011, 6, 172.	2.7	43
119	Stability of radiomic features in CT perfusion maps. Physics in Medicine and Biology, 2016, 61, 8736-8749.	3.0	43
120	Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group "Stereotactic Radiotherapy― Journal of Thoracic Disease, 2017, 9, 4512-4522.	1.4	43
121	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. International Journal of Radiation Oncology Biology Physics, 2017, 98, 511-520.	0.8	42
122	Combined CT radiomics of primary tumor and metastatic lymph nodes improves prediction of loco-regional control in head and neck cancer. Scientific Reports, 2019, 9, 15198.	3.3	42
123	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.6	40
124	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. International Journal of Radiation Oncology Biology Physics, 2020, 107, 579-586.	0.8	40
125	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
126	Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: AÂsystematic review and meta-analysis. European Journal of Cancer, 2022, 166, 254-269.	2.8	40

#	Article	IF	CITATIONS
127	Influence of retrospective sorting on image quality in respiratory correlated computed tomography. Radiotherapy and Oncology, 2007, 85, 223-231.	0.6	39
128	Detection Rate and Localization of Prostate Cancer Recurrence Using <sup>68</sup> Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤0.5 ng/mL. Journal of Nuclear Medicine, 2020, 61, 194-201.	5.0	39
129	Effect of Breathing Motion in Radiotherapy of Breast Cancer. Strahlentherapie Und Onkologie, 2009, 185, 425-430.	2.0	38
130	Stereotactic Radiosurgery for Multiple Brain Metastases. Current Treatment Options in Neurology, 2019, 21, 6.	1.8	38
131	Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 134-141.	0.8	37
132	Spinal metastases: Is stereotactic body radiation therapy supported by evidences?. Critical Reviews in Oncology/Hematology, 2016, 98, 147-158.	4.4	37
133	Mobile Health Technologies for Continuous Monitoring of Cancer Patients in Palliative Care Aiming to Predict Health Status Deterioration: A Feasibility Study. Journal of Palliative Medicine, 2020, 23, 678-685.	1.1	37
134	Analysis of the Heat Shock Response of Neisseria meningitidis with cDNA- and Oligonucleotide-Based DNA Microarrays. Journal of Bacteriology, 2002, 184, 2546-2551.	2.2	36
135	Accuracy of Real-time Couch Tracking During 3-dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, and Volumetric Modulated Arc Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 237-242.	0.8	36
136	Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiotherapy and Oncology, 2018, 127, 246-252.	0.6	36
137	Treatment plan quality during online adaptive re-planning. Radiation Oncology, 2020, 15, 203.	2.7	36
138	The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2016, 146, w14279.	1.6	35
139	Motion Compensation in Radiotherapy. Critical Reviews in Biomedical Engineering, 2012, 40, 187-197.	0.9	34
140	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
141	Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
142	Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?. Radiation Oncology, 2008, 3, 3.	2.7	33
143	Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stageÂIII non-small cell lung cancer. Strahlentherapie Und Onkologie, 2012, 188, 894-900.	2.0	33
144	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. Clinical Lung Cancer, 2019, 20, e667-e677.	2.6	33

#	Article	IF	CITATIONS
145	Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective. Radiation Oncology, 2016, 11, 7.	2.7	32
146	Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. Practical Radiation Oncology, 2018, 8, e71-e78.	2.1	32
147	Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity. Frontiers in Oncology, 2018, 8, 551.	2.8	32
148	Moderately hypofractionated radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2014, 190, 48-53.	2.0	31
149	Target delineation variability and corresponding margins of peripheral early stage NSCLC treated with stereotactic body radiotherapy. Radiotherapy and Oncology, 2015, 114, 361-366.	0.6	31
150	Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial. Radiation Oncology, 2017, 12, 161.	2.7	31
151	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	7.7	31
152	Planning comparison of five automated treatment planning solutions for locally advanced head and neck cancer. Radiation Oncology, 2018, 13, 170.	2.7	30
153	The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases. Expert Review of Anticancer Therapy, 2018, 18, 887-900.	2.4	30
154	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. Clinical and Translational Radiation Oncology, 2019, 18, 104-112.	1.7	30
155	Side Effects 15 Years After Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925. Journal of the National Cancer Institute, 2021, 113, 1360-1368.	6.3	30
156	A novel respiratory motion compensation strategy combining gated beam delivery and mean target position concept – A compromise between small safety margins and long duty cycles. Radiotherapy and Oncology, 2011, 98, 317-322.	0.6	29
157	Prediction of Early Death in Patients with Early-Stage NSCLC—Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?. Journal of Thoracic Oncology, 2016, 11, 1132-1139.	1.1	29
158	Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiation Oncology, 2018, 13, 10.	2.7	29
159	Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiotherapy and Oncology, 2020, 142, 217-223.	0.6	29
160	Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. Radiation Oncology, 2021, 16, 84.	2.7	29
161	Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer. Anticancer Research, 2018, 38, 685-690.	1.1	29
162	Radiomic biomarkers for head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2020, 196, 868-878.	2.0	28

#	Article	IF	CITATIONS
163	The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. Oncotarget, 2017, 8, 23702-23712.	1.8	28
164	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	2.7	27
165	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1219.	2.8	27
166	Current status and recent advances in resection cavity irradiation of brain metastases. Radiation Oncology, 2021, 16, 73.	2.7	27
167	FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Research, 2020, 10, 81.	2.5	27
168	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	2.8	27
169	Semi-robotic 6 degree of freedom positioning for intracranial high precision radiotherapy; first phantom and clinical results. Radiation Oncology, 2010, 5, 42.	2.7	26
170	Optimization of combined proton–photon treatments. Radiotherapy and Oncology, 2018, 128, 133-138.	0.6	26
171	A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. Radiotherapy and Oncology, 2020, 150, 1-3.	0.6	26
172	Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. European Respiratory Journal, 2022, 59, 2004503.	6.7	26
173	Influence of Continuous Table Motion on Patient Breathing Patterns. International Journal of Radiation Oncology Biology Physics, 2010, 77, 622-629.	0.8	25
174	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 129, 63-71.	2.0	25
175	Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm, 2021, 18, 2137-2145.	0.7	25
176	Clinical Outcome of Dose-Escalated Image-Guided Radiotherapy for Spinal Metastases. International Journal of Radiation Oncology Biology Physics, 2009, 75, 828-835.	0.8	24
177	Comparison of a multileaf collimator tracking system and a robotic treatment couch tracking system for organ motion compensation during radiotherapy. Medical Physics, 2012, 39, 7032-7041.	3.0	24
178	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. BMC Cancer, 2012, 12, 530.	2.6	24
179	SBRT for centrally localized NSCLC – What is too central?. Radiation Oncology, 2016, 11, 157.	2.7	24
180	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. Cancers, 2019, 11, 472.	3.7	24

#	Article	IF	CITATIONS
181	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	2.7	24
182	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.6	24
183	Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Practical Radiation Oncology, 2020, 10, e452-e460.	2.1	24
184	Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. International Journal of Cancer, 2021, 149, 358-370.	5.1	24
185	Distinct effects of rectum delineation methods in 3D-confromal vs. IMRT treatment planning of prostate cancer. Radiation Oncology, 2006, 1, 34.	2.7	23
186	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.8	23
187	Long-term quality-of-life after neoadjuvant short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. Radiotherapy and Oncology, 2013, 108, 326-330.	0.6	23
188	Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases. Strahlentherapie Und Onkologie, 2014, 190, 1141-1148.	2.0	23
189	Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. Strahlentherapie Und Onkologie, 2014, 190, 377-381.	2.0	23
190	Tumour delineation in oesophageal cancer – A prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Radiotherapy and Oncology, 2015, 116, 269-275.	0.6	23
191	Three-dimensional versus four-dimensional dose calculation for volumetric modulated arc therapy of hypofractionated treatments. Zeitschrift Fur Medizinische Physik, 2016, 26, 45-53.	1.5	23
192	Doseâ€intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. Cancer, 2018, 124, 2001-2009.	4.1	23
193	Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 132-141.	0.8	23
194	Predisposing and precipitating risk factors for delirium in palliative care patients. Palliative and Supportive Care, 2020, 18, 437-446.	1.0	23
195	Comparison of robust to standardized CT radiomics models to predict overall survival for nonâ€small cell lung cancer patients. Medical Physics, 2020, 47, 4045-4053.	3.0	23
196	Evalution of surface-based deformable image registration for adaptive radiotherapy of non-small cell lung cancer (NSCLC). Radiation Oncology, 2009, 4, 68.	2.7	22
197	Interchangeability of radiomic features between [18F]â€ <scp>FDG PET</scp> / <scp>CT</scp> and [18F]â€ <scp>FDG PET</scp> / <scp>MR</scp> . Medical Physics, 2019, 46, 1677-1685.	3.0	22
198	Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiotherapy and Oncology, 2020, 142, 210-216.	0.6	22

#	Article	IF	CITATIONS
199	Carbon Fiber/Polyether Ether Ketone (CF/PEEK) Implants Allow for More Effective Radiation in Long Bones. Materials, 2020, 13, 1754.	2.9	22
200	Distance to isocenter is not associated with an increased risk for local failure in LINAC-based single-isocenter SRS or SRT for multiple brain metastases. Radiotherapy and Oncology, 2021, 159, 168-175.	0.6	22
201	Adverse effect of a distended rectum in intensity-modulated radiotherapy (IMRT) treatment planning of prostate cancer. Radiotherapy and Oncology, 2006, 79, 59-64.	0.6	21
202	Stereotactic body radiotherapy: A survey of contemporary practice in six selected European countries. Acta Oncológica, 2015, 54, 1237-1241.	1.8	21
203	ELPHA: Dynamically deformable liver phantom for realâ€ŧime motionâ€adaptive radiotherapy treatments. Medical Physics, 2019, 46, 839-850.	3.0	21
204	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of Thoracic Oncology, 2019, 14, 115-123.	1.1	21
205	Influence of Rectum Delineation (Rectal Volume vs. Rectal Wall) on IMRT Treatment Planning of the Prostate. Strahlentherapie Und Onkologie, 2006, 182, 721-726.	2.0	20
206	Comparison of Wedge versus Segmented Techniques in Whole Breast Irradiation. Strahlentherapie Und Onkologie, 2008, 184, 307-312.	2.0	20
207	Required target margins for image-guided lung SBRT: Assessment of target position intrafraction and correction residuals. Practical Radiation Oncology, 2013, 3, 67-73.	2.1	20
208	A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015. PLoS ONE, 2016, 11, e0148312.	2.5	20
209	"HEATPACâ€+ a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Radiation Oncology, 2017, 12, 183.	2.7	20
210	Performance comparison of prediction filters for respiratory motion tracking in radiotherapy. Medical Physics, 2020, 47, 643-650.	3.0	20
211	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	2.6	20
212	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU International, 2021, 127, 703-711.	2.5	20
213	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the †TOaSTT' database. Radiation Oncology, 2021, 16, 4.	2.7	20
214	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. European Urology Focus, 2021, 7, 241-244.	3.1	20
215	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial Journal of Clinical Oncology, 2018, 36, 8510-8510.	1.6	20
216	Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study. Radiotherapy and Oncology, 2022, 168, 256-264.	0.6	20

#	Article	IF	CITATIONS
217	Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer. Strahlentherapie Und Onkologie, 2016, 192, 875-885.	2.0	19
218	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 94, 841-849.	0.8	19
219	Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group. Clinical Lung Cancer, 2017, 18, 162-168.	2.6	19
220	Short interactive workshops reduce variability in contouring treatment volumes for spine stereotactic body radiation therapy: Experience with the ESTRO FALCON programme and EduCaseâ,,¢ training tool. Radiotherapy and Oncology, 2018, 127, 150-153.	0.6	19
221	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. World Journal of Urology, 2019, 37, 457-467.	2.2	19
222	Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. Strahlentherapie Und Onkologie, 2019, 195, 199-206.	2.0	19
223	Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated EQD2 doses. Radiotherapy and Oncology, 2020, 152, 56-62.	0.6	19
224	Combined proton–photon treatments – A new approach to proton therapy without a gantry. Radiotherapy and Oncology, 2020, 145, 81-87.	0.6	19
225	Mid-Ventilation Concept for Mobile Pulmonary Tumors: Internal Tumor Trajectory Versus Selective Reconstruction of Four-Dimensional Computed Tomography Frames Based on External Breathing Motion. International Journal of Radiation Oncology Biology Physics, 2009, 74, 602-609.	0.8	18
226	Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlentherapie Und Onkologie, 2011, 187, 548-554.	2.0	18
227	Suitability of markerless EPID tracking for tumor position verification in gated radiotherapy. Medical Physics, 2014, 41, 031702.	3.0	18
228	Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDG uptake in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2015, 117, 125-131.	0.6	18
229	Validation of dynamic treatment-couch tracking for prostate SBRT. Medical Physics, 2017, 44, 2466-2477.	3.0	18
230	Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study. Radiotherapy and Oncology, 2019, 141, 62-66.	0.6	18
231	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics. 2022. 113. 1015-1024.	0.8	18
232	Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study. Radiotherapy and Oncology, 2022, 173, 269-276.	0.6	18
233	Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: Importance of baseline symptoms and of prostate-V150. Radiotherapy and Oncology, 2009, 91, 217-224.	0.6	17
234	Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. Strahlentherapie Und Onkologie, 2012, 188, 551-557.	2.0	17

#	Article	IF	CITATIONS
235	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. Strahlentherapie Und Onkologie, 2018, 194, 365-374.	2.0	17
236	Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. Frontiers in Oncology, 2020, 10, 578895.	2.8	17
237	Head and neck radiotherapy on the MR linac: aÂmulticenter planning challenge amongst MRIdian platform users. Strahlentherapie Und Onkologie, 2021, 197, 1093-1103.	2.0	17
238	mHealth Technologies for Palliative Care Patients at the Interface of In-Patient to Outpatient Care: Protocol of Feasibility Study Aiming to Early Predict Deterioration of Patient's Health Status. JMIR Research Protocols, 2017, 6, e142.	1.0	17
239	Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer. Radiotherapy and Oncology, 2022, 170, 205-212.	0.6	17
240	Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results. Radiation Oncology, 2009, 4, 67.	2.7	16
241	Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): Solid evidence or "no-go�. Radiotherapy and Oncology, 2013, 109, 178-179.	0.6	16
242	Prospective randomized clinical studies involving reirradiation. Strahlentherapie Und Onkologie, 2016, 192, 679-686.	2.0	16
243	Preserving the legacy of reirradiation: A narrative review of historical publications. Advances in Radiation Oncology, 2017, 2, 176-182.	1.2	16
244	Comparison of multi-leaf collimator tracking and treatment-couch tracking during stereotactic body radiation therapy of prostate cancer. Radiotherapy and Oncology, 2017, 125, 445-452.	0.6	16
245	Second re-irradiation: a narrative review of the available clinical data. Acta Oncológica, 2018, 57, 305-310.	1.8	16
246	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863.	6.4	16
247	Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. British Journal of Radiology, 2021, 94, 20200947.	2.2	16
248	A comparison between 2-Step IMRT and conventional IMRT planning. Radiotherapy and Oncology, 2007, 84, 298-306.	0.6	15
249	Variability in spine radiosurgery treatment planning – results of an international multi-institutional study. Radiation Oncology, 2016, 11, 57.	2.7	15
250	Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy. Radiotherapy and Oncology, 2017, 125, 357-364.	0.6	15
251	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 395.	2.6	15
252	Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: The impact of a local dose–effect relationship for lung perfusion loss. Radiotherapy and Oncology, 2019, 132, 142-147.	0.6	15

#	Article	IF	CITATIONS
253	The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. European Journal of Cancer, 2020, 131, 76-88.	2.8	15
254	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology, 2021, 11, 636672.	2.8	15
255	Long-Term Results of Dose-Intensified Fractionated Stereotactic Body Radiation Therapy (SBRT) for Painful Spinal Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 110, 348-357.	0.8	15
256	Radiation recall dermatitis induced by sorafenib. Strahlentherapie Und Onkologie, 2016, 192, 342-348.	2.0	14
257	Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. Tumori, 2018, 104, 148-156.	1.1	14
258	Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma – Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. Frontiers in Oncology, 2021, 11, 664304.	2.8	14
259	Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infection Control and Hospital Epidemiology, 2021, 42, 268-273.	1.8	14
260	The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial. Radiotherapy and Oncology, 2022, 172, 99-110.	0.6	14
261	A multi-national report on methods for institutional credentialing for spine radiosurgery. Radiation Oncology, 2013, 8, 158.	2.7	13
262	Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 893-899.	0.8	13
263	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stageÂl disease. Strahlentherapie Und Onkologie, 2017, 193, 515-524.	2.0	13
264	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer. BJU International, 2017, 120, E45-E51.	2.5	13
265	Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results. Radiotherapy and Oncology, 2019, 132, 63-69.	0.6	13
266	Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. European Journal of Cancer, 2020, 124, 194-203.	2.8	13
267	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
268	Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. Physics and Imaging in Radiation Oncology, 2020, 16, 109-112.	2.9	13
269	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
270	Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking. Radiotherapy and Oncology, 2021, 156, 145-152.	0.6	13

#	Article	IF	CITATIONS
271	MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. Cancers, 2021, 13, 5404.	3.7	13
272	Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. Radiation Oncology, 2021, 16, 217.	2.7	13
273	Non-parametric intravoxel incoherent motion analysis in patients with intracranial lesions: Test-retest reliability and correlation with arterial spin labeling. NeuroImage: Clinical, 2016, 11, 780-788.	2.7	12
274	Technical knowâ€how in stereotactic ablative radiotherapy ( <scp>SABR</scp> ). Journal of Medical Radiation Sciences, 2016, 63, 5-8.	1.5	12
275	Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer. Radiation Oncology, 2017, 12, 175.	2.7	12
276	Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report. Neuro-Oncology, 2018, 20, 1215-1224.	1.2	12
277	Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. Frontiers in Oncology, 2019, 9, 961.	2.8	12
278	Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy. Radiation Oncology, 2020, 15, 266.	2.7	12
279	Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. Translational Lung Cancer Research, 2021, 10, 1960-1968.	2.8	12
280	Image-guided Radiotherapy Based on Kilovoltage Cone-beam Computed Tomography — A Review of Technology and Clinical Outcome. European Oncology and Haematology, 2011, 07, 121.	0.0	12
281	Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study. Physics and Imaging in Radiation Oncology, 2022, 22, 131-136.	2.9	12
282	MR-guided beam gating: Residual motion, gating efficiency and dose reconstruction for stereotactic treatments of the liver and lung. Radiotherapy and Oncology, 2022, 174, 101-108.	0.6	12
283	Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation. Radiation Oncology, 2012, 7, 103.	2.7	11
284	Dose and Fractionation in Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: Lessons Learned and Where Do We Go Next?. International Journal of Radiation Oncology Biology Physics, 2015, 93, 765-768.	0.8	11
285	The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy and Oncology, 2017, 124, 433-438.	0.6	11
286	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
287	Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis. Strahlentherapie Und Onkologie, 2021, 197, 124-132.	2.0	11
288	An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 2021, 6, 100653.	1.2	11

#	Article	IF	CITATIONS
289	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	2.8	11
290	Systematic Review on the Association of Radiomics with Tumor Biological Endpoints. Cancers, 2021, 13, 3015.	3.7	11
291	Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1222-1233.	0.8	11
292	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. EJNMMI Research, 2021, 11, 79.	2.5	11
293	Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer Journal of Clinical Oncology, 2018, 36, 504-504.	1.6	11
294	Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open, 2022, 7, 100455.	4.5	11
295	Oligometastasis in breast cancer—current status and treatment options from aÂradiation oncology perspective. Strahlentherapie Und Onkologie, 2022, 198, 601-611.	2.0	11
296	Four Dimensional Target Volume Generation in Pulmonary Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, S191.	0.8	10
297	Influence of increased target dose inhomogeneity on margins for breathing motion compensation in conformal stereotactic body radiotherapy. BMC Medical Physics, 2008, 8, 5.	2.4	10
298	Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma. Acta Oncológica, 2019, 58, 1514-1518.	1.8	10
299	Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology. Journal of Neuro-Oncology, 2021, 152, 395-404.	2.9	10
300	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial Journal of Clinical Oncology, 2021, 39, 194-194.	1.6	10
301	Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. Translational Lung Cancer Research, 2021, 10, 1930-1949.	2.8	10
302	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiotherapy and Oncology, 2021, 164, 104-114.	0.6	10
303	Single-isocenter versus multiple-isocenters for multiple lung metastases: Evaluation of lung dose. Radiotherapy and Oncology, 2022, 166, 189-194.	0.6	10
304	Patterns of Care in the Radiotherapy of Prostate Cancer in Northern Bavaria 1998–2000. Strahlentherapie Und Onkologie, 2007, 183, 314-320.	2.0	9
305	Risk for surgical complications after previous stereotactic body radiotherapy of the spine. Radiation Oncology, 2017, 12, 153.	2.7	9
306	A Bayesian network model of lymphatic tumor progression for personalized elective CTV definition in head and neck cancers. Physics in Medicine and Biology, 2019, 64, 165003.	3.0	9

#	Article	IF	CITATIONS
307	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infection Control and Hospital Epidemiology, 2022, 43, 312-318.	1.8	9
308	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	2.6	9
309	Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer. Radiation Oncology, 2021, 16, 189.	2.7	9
310	A 2.5D convolutional neural network for HPV prediction in advanced oropharyngeal cancer. Computers in Biology and Medicine, 2022, 142, 105215.	7.0	9
311	Three-dimensional spatial modelling of the correlation between abdominal motion and lung tumour motion with breathing. Acta Oncolųgica, 2006, 45, 923-934.	1.8	8
312	Stereotactic Body Radiotherapy for Stage I NSCLC: The Challenge of Evidence-Based Medicine. Journal of Thoracic Oncology, 2014, 9, e17-e18.	1.1	8
313	The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncology, 2015, 11, 2721-2733.	2.4	8
314	Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement – A Qualitative Study. Integrative Cancer Therapies, 2018, 17, 762-773.	2.0	8
315	Stereotactic Image Guided Lung Radiation Therapy for Clinical Early Stage Non-Small Cell Lung Cancer: A Long-Term Report From a Multi-Institutional Database of Patients Treated With or Without a Pathologic Diagnosis. Practical Radiation Oncology, 2020, 10, e227-e237.	2.1	8
316	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. Radiation Oncology, 2020, 15, 135.	2.7	8
317	Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy. Radiation Oncology, 2020, 15, 24.	2.7	8
318	68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer. Annals of Nuclear Medicine, 2021, 35, 1109-1116.	2.2	8
319	International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2022, 112, 351-360.	0.8	8
320	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	3.7	8
321	Transperineal Injection of Hyaluronic Acid in Anterior Perirectal Fat to Decrease Rectal Toxicity From Radiation Delivered With Intensity-Modulated Brachytherapy or EBRT for Prostate Cancer Patients: In Regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95–102.). International Journal of Radiation Oncology Biology Physics, 2008, 71, 316-317.	0.8	7
322	Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlentherapie Und Onkologie, 2013, 189, 1040-1048.	2.0	7
323	Perspectives on oligometastasis: challenges and opportunities. Journal of Thoracic Disease, 2018, 10, 113-117.	1.4	7
324	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. Journal of Neuro-Oncology, 2019, 145, 339-347.	2.9	7

#	Article	IF	CITATIONS
325	Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer—A Multicenter Study. Frontiers in Oncology, 2019, 9, 932.	2.8	7
326	Histopathological Findings After Reirradiation Compared to First Irradiation of Spinal Bone Metastases With Stereotactic Body Radiotherapy: A Cohort Study. Neurosurgery, 2019, 84, 435-441.	1.1	7
327	Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 17, 43-46.	2.9	7
328	High-dose re-irradiation of intracranial lesions – Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose calculation. Clinical and Translational Radiation Oncology, 2021, 27, 132-138.	1.7	7
329	The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas. Clinical and Translational Radiation Oncology, 2021, 27, 109-113.	1.7	7
330	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2021, 158, 40-47.	0.6	7
331	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. Radiotherapy and Oncology, 2021, 159, 17-20.	0.6	7
332	Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose. Strahlentherapie Und Onkologie, 2021, 197, 836-846.	2.0	7
333	Accounting for Range Uncertainties in the Optimization of Combined Proton-Photon Treatments Via Stochastic Optimization. International Journal of Radiation Oncology Biology Physics, 2020, 108, 792-801.	0.8	7
334	Radiation holidays stimulate tumor immunity. Oncotarget, 2015, 6, 15716-15717.	1.8	7
335	SBRT in operable early stage lung cancer patients. Translational Lung Cancer Research, 2014, 3, 212-24.	2.8	7
336	Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective. Radiotherapy and Oncology, 2022, 172, 23-31.	0.6	7
337	Stereotactic Body Radiation Therapy for Metastases in Long Bones. International Journal of Radiation Oncology Biology Physics, 2022, 114, 738-746.	0.8	7
338	Dosimetric consequences of inter-fraction breathing-pattern variation on radiotherapy with personalized motion-assessed margins. Physics in Medicine and Biology, 2011, 56, 7033-7043.	3.0	6
339	Modeling and performance evaluation of a robotic treatment couch for tumor tracking. Biomedizinische Technik, 2016, 61, 557-566.	0.8	6
340	Changes in penile bulb dose when using the Clarity transperineal ultrasound probe: A planning study. Practical Radiation Oncology, 2016, 6, e337-e344.	2.1	6
341	Interobserver variability in target volume delineation of hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2017, 193, 823-830.	2.0	6
342	Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma. British Journal of Radiology, 2019, 92, 20190113.	2.2	6

#	Article	IF	CITATIONS
343	The American Society of Clinical Oncology–endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non–small cell lung cancer: An expert opinion. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 358-361.	0.8	6
344	Radiotherapy of the oldest old—feasibility and institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 683-690.	2.0	6
345	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Scientific Reports, 2021, 11, 4590.	3.3	6
346	Quality-of-life and toxicity in cancer patients treated with multiple courses of radiation therapy. Clinical and Translational Radiation Oncology, 2022, 34, 23-29.	1.7	6
347	Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model. Neoplasia, 2022, 31, 100812.	5.3	6
348	Intensity-modulated radiotherapy for the treatment of pelvic lymph nodes in prostate cancer. Future Oncology, 2007, 3, 43-47.	2.4	5
349	In Regard to Koshy et al. International Journal of Radiation Oncology Biology Physics, 2015, 92, 945-946.	0.8	5
350	Time forÂstandardization of SBRT planning throughÂlarge scale clinical dataÂand guideline-based approaches. Strahlentherapie Und Onkologie, 2017, 193, 1068-1069.	2.0	5
351	The ideal couch tracking system—Requirements and evaluation of current systems. Journal of Applied Clinical Medical Physics, 2019, 20, 152-159.	1.9	5
352	Analysis of lymphatic metastasis and progression patterns for clinical target volume (CTV) definition in head and neck squamous cell carcinoma (HNSCC). Acta Oncológica, 2019, 58, 1519-1522.	1.8	5
353	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Research, 2020, 30, 552-561.	1.2	5
354	A pattern of care analysis: Prosthetic rehabilitation of head and neck cancer patients after radiotherapy. Clinical Implant Dentistry and Related Research, 2020, 22, 333-341.	3.7	5
355	Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. Radiation Oncology, 2021, 16, 64.	2.7	5
356	Long-term cancer survivors treated with multiple courses of repeat radiation therapy. Radiation Oncology, 2021, 16, 208.	2.7	5
357	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
358	Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface. Radiotherapy and Oncology, 2022, 169, 1-7.	0.6	5
359	Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus?. International Journal of Radiation Oncology Biology Physics, 2022, 112, 586-589.	0.8	5
360	SBRT for Central Tumors in Early Stage NSCLC Patients. International Journal of Radiation Oncology Biology Physics, 2017, 99, S17.	0.8	4

#	Article	IF	CITATIONS
361	PO-0932: Combining deep learning and radiomics to predict HPV status in oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 2018, 127, S504-S505.	0.6	4
362	Margin calculation for multiple lung metastases treated with single-isocenter SBRT. Radiotherapy and Oncology, 2021, 162, 105-111.	0.6	4
363	4D-CT-based motion correction of PET images using 3D iterative deconvolution. Oncotarget, 2019, 10, 2987-2995.	1.8	4
364	What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?. Journal of Thoracic Disease, 2011, 3, 147-9.	1.4	4
365	Computed-tomography-based radiomics features for staging of interstitial lung disease – transferability from experimental to human lung fibrosis - a proof-of-concept study. , 2019, , .		4
366	Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. Oncology Reports, 2007, 18, 1335-9.	2.6	4
367	Stereotactic body radiotherapy of adrenal metastases—A doseâ€finding study. International Journal of Cancer, 2022, 151, 412-421.	5.1	4
368	Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2022, , 1.	2.0	4
369	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiotherapy and Oncology, 2022, 172, 1-9.	0.6	4
370	Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Lung Cancer, 2022, 170, 185-193.	2.0	4
371	SBRT for Lung Metastases: A Pooled Analysis of 651 Patients and 868 Lesions of the German Working Group Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S31.	0.8	3
372	SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation. Journal of Thoracic Disease, 2016, 8, 2305-2309.	1.4	3
373	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. Cancer Treatment and Research Communications, 2018, 17, 18-22.	1.7	3
374	Body motion during dynamic couch tracking with healthy volunteers. Physics in Medicine and Biology, 2019, 64, 015001.	3.0	3
375	Should stereotactic radiotherapy be the preferred treatment for oligometastatic disease?. Lancet Oncology, The, 2021, 22, 1067-1068.	10.7	3
376	Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy. Clinical and Translational Radiation Oncology, 2021, 30, 26-30.	1.7	3
377	Abstract LB-151: The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity in combination with bevacizumab. Cancer Research, 2017, 77, LB-151-LB-151.	0.9	3
378	Quantification of theÂspatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports, 2021, 11, 20890.	3.3	3

#	Article	IF	CITATIONS
379	Probing spatiotemporal fractionation on the preclinical level. Physics in Medicine and Biology, 2020, 65, 22NT02.	3.0	3
380	A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?. Annals of Translational Medicine, 2015, 3, 148.	1.7	3
381	A dataset on patient-individual lymph node involvement in oropharyngeal squamous cell carcinoma. Data in Brief, 2022, 43, 108345.	1.0	3
382	An Interlaced IMRT Technique for Elongated Tumor Volumes. Medical Dosimetry, 2009, 34, 170-178.	0.9	2
383	NTCP Modeling for Radiation Pneumonitis after SBRT for Malignant Pulmonary Lesions: Results of a Multi-institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 81, S28-S29.	0.8	2
384	Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence?. Expert Review of Anticancer Therapy, 2015, 15, 525-530.	2.4	2
385	198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation. Journal of Thoracic Oncology, 2016, 11, S143.	1.1	2
386	Reirradiation Stereotactic Body Radiation Therapy (SBRT) for Spinal Metastases: A Multi-Institutional Outcome Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, S123-S124.	0.8	2
387	Unconscious physiological response of healthy volunteers to dynamic respiration-synchronized couch motion. Radiation Oncology, 2017, 12, 189.	2.7	2
388	Correspondence on Rajyaguru et al. Journal of Clinical Oncology, 2018, 36, 2561-2562.	1.6	2
389	EP-2197: Dose normalization in lung SBRT based on ICRU 91 and comparison to alterative normalization methods. Radiotherapy and Oncology, 2018, 127, S1213-S1214.	0.6	2
390	Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: another step forward on the long road of evidence-based medicine for oligometastatic disease. Journal of Thoracic Disease, 2019, 11, S1869-S1873.	1.4	2
391	Response letter: Handling of COVID-19 positive lung cancer patients during the pandemic. Radiotherapy and Oncology, 2020, 147, 231.	0.6	2
392	Radiotherapy for glioblastoma patients with poor performance status. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2127-2136.	2.5	2
393	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10 Journal of Clinical Oncology, 2015, 33, 5038-5038.	1.6	2
394	Inhibition of N-Myc down regulated gene 1 inin vitrocultured human glioblastoma cells. World Journal of Clinical Oncology, 2012, 3, 104.	2.3	2
395	A Novel Radiomics-Based Tumor Volume Segmentation Algorithm for Lung Tumors in FDG-PET/CT after 3D Motion Correction—A Technical Feasibility and Stability Study. Diagnostics, 2022, 12, 576.	2.6	2
396	Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. Radiotherapy and Oncology, 2022, 170, 95-101.	0.6	2

#	Article	IF	CITATIONS
397	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. Frontiers in Oncology, 2022, 12, 830627.	2.8	2
398	Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life. Clinical and Translational Radiation Oncology, 2022, 34, 107-111.	1.7	2
399	Influence of Delineation of the Proximal and Distal Rectum as Separated Organ-at-Risks on IMRT Treatment Planning for the Prostate. International Journal of Radiation Oncology Biology Physics, 2005, 63, S498.	0.8	1
400	Erratum to "Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): Results of a serial follow-up CT study―[Radiother Oncol 85 (2007) 435–442]. Radiotherapy and Oncology, 2008, 86, 293.	0.6	1
401	A Multinational Report on Methods for Delivery of Lung Stereotactic Radiotherapy (SBRT) using Online Volumetric Image-guidance (VIGRT): Results from the Synergy Research Group. International Journal of Radiation Oncology Biology Physics, 2009, 75, S159-S160.	0.8	1
402	A Collaborative Analysis of Stereotactic Lung Radiotherapy (Lung SBRT) Outcomes for Stage I Non-small Cell Lung Cancer (NSCLC) using Daily Online Cone-beam CT Image-guided Radiotherapy (CBCT-IGRT). International Journal of Radiation Oncology Biology Physics, 2010, 78, S14.	0.8	1
403	Predictive Value of Radiomics Analysis for Local Tumor Control After Radiochemotherapy in Patients With Head and Neck cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, S117.	0.8	1
404	An International Radiosurgery Consortium Survey for Gynecological Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E300.	0.8	1
405	Optimal Imaging Follow-up Schedules after Stereotactic Ablative Radiotherapy for Early Non-Small-Cell Lung Cancer: Findings of an International Delphi Consensus Study. International Journal of Radiation Oncology Biology Physics, 2017, 99, S241-S242.	0.8	1
406	Performance behavior of prediction filters for respiratory motion compensation in radiotherapy. Current Directions in Biomedical Engineering, 2017, 3, 429-432.	0.4	1
407	Optimizing a perfusion CT protocol for head and neck cancer. Current Directions in Biomedical Engineering, 2017, 3, 591-594.	0.4	1
408	Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival. Annals of Oncology, 2019, 30, ii63.	1.2	1
409	PV-0312 Distributed learning in radiomics to predict overall survival in head and neck cancer. Radiotherapy and Oncology, 2019, 133, S160-S161.	0.6	1
410	PV-0315 A risk assessment method including credible intervals for lymphatic metastatic spread for HNSCC. Radiotherapy and Oncology, 2019, 133, S163.	0.6	1
411	Dependency of the blood oxygen level dependent-response to hyperoxic challenges on the order of gas administration in intracranial malignancies. Neuroradiology, 2019, 61, 783-793.	2.2	1
412	Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug. Lung Cancer, 2020, 146, 217-223.	2.0	1
413	In Regard to Ohri etÂal. International Journal of Radiation Oncology Biology Physics, 2021, 110, 249-250.	0.8	1
414	X-change symposium: status and future of modern radiation oncology—from technology to biology. Radiation Oncology, 2021, 16, 27.	2.7	1

#	Article	IF	CITATIONS
415	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition Journal of Clinical Oncology, 2019, 37, 9575-9575.	1.6	1
416	Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. Oncology Reports, 0, , .	2.6	1
417	FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer, 2022, 22, 359.	2.6	1
418	Prospective assessment of stress and health concerns of radiation oncology staff during the COVID-19 pandemic. Clinical and Translational Radiation Oncology, 2022, 35, 110-117.	1.7	1
419	Reliability of Bony Anatomy in Image-Guided Stereotactic Radiotherapy of Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2007, 69, S249.	0.8	Ο
420	Real-time Couch Tracking for Prostate Cancer: Toward Submillimeter Accuracy. International Journal of Radiation Oncology Biology Physics, 2010, 78, S678-S679.	0.8	0
421	Reduced Normal Tissue Doses Through Advanced Technology. Medical Radiology, 2010, , 59-84.	0.1	Ο
422	A Multi-national Report on Methods of Image-guided Stereotactic Body Radiotherapy and Radiosurgery for Vertebral Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 81, S130-S131.	0.8	0
423	Gene expression inhibition of N-Myc downregulated gene 1 (NDRG1) monitoring and facilitation via transfectional transfer of NDRG1-siRNA constructs into- in vitro-cultured human glioblastoma cells. , 2011, , .		Ο
424	Radiographic Changes After Lung Stereotactic Ablative Radiation Therapy (SABR) - Can We Distinguish Fibrosis From Recurrence? A Systematic Review of the Literature. International Journal of Radiation Oncology Biology Physics, 2012, 84, S554.	0.8	0
425	Variability in Spine Radiosurgery Treatment Planning Results of an International Multi-institutional Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, S195-S196.	0.8	Ο
426	Radiosurgery as Primary Treatment for Vertebral Metastases: Results From an International Multicenter Database. International Journal of Radiation Oncology Biology Physics, 2013, 87, S102.	0.8	0
427	Skull Base Tumors. , 2015, , 483-498.		Ο
428	Stereotactic body radiotherapy for central lung tumours: <i>Author reply</i> . British Journal of Radiology, 2015, 88, 20150532.	2.2	0
429	Results of the Planning Comparison Study SBRT of NSCLC. International Journal of Radiation Oncology Biology Physics, 2015, 93, E573.	0.8	Ο
430	Reduced Normal Tissue Doses Through Advanced Technology. Medical Radiology, 2016, , 75-103.	0.1	0
431	SP-0311: Automated treatment plan generation - the Zurich experience. Radiotherapy and Oncology, 2016, 119, S144-S145.	0.6	0
432	EP-1748: An experimental comparison of advanced respiratory motion management techniques. Radiotherapy and Oncology, 2016, 119, S818-S819.	0.6	0

#	Article	IF	CITATIONS
433	SBRT in eight fractions. International Journal of Radiation Oncology Biology Physics, 2017, 97, 653.	0.8	0
434	Stereotactic Body Radiotherapy. Medical Radiology, 2017, , 323-395.	0.1	0
435	SC03.01 Advances in Stereotactic Body Radiotherapy. Journal of Thoracic Oncology, 2017, 12, S80-S81.	1.1	0
436	P2.05-044 Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases. Journal of Thoracic Oncology, 2017, 12, S1058-S1059.	1.1	0
437	International Collaborative Propensity-Based Matched Pair Analysis of Operable Early Stage Lung Ancer Patients Treated with Stereotactic Body Radiation Therapy Compared to Resection: Differences in Recurrence and Survival with Prolonged Follow-Up. International Journal of Radiation Oncology Biology Physics, 2017, 99, E456-E457.	0.8	0
438	Minimizing Immunosuppressive Effects of Photon and Proton Radiation Therapy on Circulating Lymphocytes. International Journal of Radiation Oncology Biology Physics, 2017, 99, E577-E578.	0.8	0
439	EP-1697: Does contrast agent influence the prognostic accuracy of CT radiomics based outcome modelling?. Radiotherapy and Oncology, 2017, 123, S928-S929.	0.6	0
440	OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial. Radiotherapy and Oncology, 2017, 123, S58-S59.	0.6	0
441	EP-1414: Toxicity of concurrent stereotactic radiotherapy and targeted or immunotherapy: a systematic review. Radiotherapy and Oncology, 2017, 123, S756.	0.6	0
442	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease. , 2018, , 342-354.e4.		0
443	PC08.05 Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery. Journal of Thoracic Oncology, 2018, 13, S249.	1.1	0
444	Radiotherapy dose escalation in locally advanced NSCLC – The limits of conventional radiochemotherapy. Lung Cancer, 2018, 126, 208-209.	2.0	0
445	PV-0042: SBRT for peripheral lung tumors >5 cm: first results of the multicenter phase I/II VOLUMES trial. Radiotherapy and Oncology, 2018, 127, S17-S18.	0.6	0
446	OC-0166: Dose of stereotactic radiotherapy, local control and overall survival in cholangiocarcinoma. Radiotherapy and Oncology, 2018, 127, S85-S86.	0.6	0
447	PV-0197: Comparison of manual and two automated planning solutions for stereotactic brain radiosurgery. Radiotherapy and Oncology, 2018, 127, S106-S107.	0.6	0
448	PV-0200: Benchmark Case results from the EORTC Lungtech trial of SBRT for patients with centrally NSCLC. Radiotherapy and Oncology, 2018, 127, S108-S109.	0.6	0
449	PV-0205: Optimization of combined proton-photon treatments. Radiotherapy and Oncology, 2018, 127, S112-S113.	0.6	0
450	OC-0513: In-silico comparison of five automated treatment planning solutions for primary head and neck cancer. Radiotherapy and Oncology, 2018, 127, S268-S269.	0.6	0

#	Article	IF	CITATIONS
451	OC-0617: A new technique for robust VMAT treatment planning of total craniospinal irradiation. Radiotherapy and Oncology, 2018, 127, S326-S327.	0.6	0
452	PO-0845: Histopathological findings after irradiation and re-irradiation of spinal bone metastases with SBRT. Radiotherapy and Oncology, 2018, 127, S441-S442.	0.6	0
453	PO-0900: Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy. Radiotherapy and Oncology, 2018, 127, S479-S480.	0.6	Ο
454	PO-0980: Primary tumor and lymph nodes CT radiomics to predict loco-regional control in head and neck cancer. Radiotherapy and Oncology, 2018, 127, S542-S543.	0.6	0
455	EP-1550: Radiotherapy of PSMA-positive oligometastatic recurrent prostate cancer: a single-center experience. Radiotherapy and Oncology, 2018, 127, S836.	0.6	0
456	EP-2001: A Bayesian network model for personalized elective CTV definition in head and neck cancer. Radiotherapy and Oncology, 2018, 127, S1089-S1090.	0.6	0
457	EP-2209: Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC Lungtech trial. Radiotherapy and Oncology, 2018, 127, S1220-S1221.	0.6	0
458	Stereotactic Body Radiotherapy. Progress in Tumor Research, 2018, , 67-88.	0.1	0
459	OC-0526: Can surface guided radiation therapy be used to setup DIBH breast cancer patients to reduce Imaging?. Radiotherapy and Oncology, 2018, 127, S278.	0.6	0
460	76P Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR. Journal of Thoracic Oncology, 2018, 13, S41.	1.1	0
461	MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS. Neuro-Oncology Advances, 2019, 1, i16-i16.	0.7	0
462	OC-0163 Risk classification for PSA relapse after PSMAPET-guided RT for oligorecurrent prostate cancer. Radiotherapy and Oncology, 2019, 133, S79-S80.	0.6	0
463	OC-0166 Cumulative metastases volume, not number of brain metastases predicts survival in melanoma patients. Radiotherapy and Oncology, 2019, 133, S81-S82.	0.6	0
464	EP-1229 Repeated intracranial radiotherapy/SRTAnalysis of efficacy and safety including EQD2 sum plans. Radiotherapy and Oncology, 2019, 133, S677-S678.	0.6	0
465	EP-1563 PSMA-ligand based radiotherapy for lymph node relapsed prostate cancer after radical prostatectomy. Radiotherapy and Oncology, 2019, 133, S843-S844.	0.6	0
466	OC-0059 Stereotactic radiotherapy for oligoprogressive NSCLC: clinical scenarios affecting survival. Radiotherapy and Oncology, 2019, 133, S23-S24.	0.6	0
467	Leukoencephalopathy after Prophylactic Whole-Brain Irradiation with or without Hippocampal Sparing: A Long-Term MRI Analysis. International Journal of Radiation Oncology Biology Physics, 2019, 105, E79.	0.8	0
468	PO-0923 How can a limited number of proton slots be optimally used in combined proton-photon treatments?. Radiotherapy and Oncology, 2019, 133, S494-S495.	0.6	0

#	Article	IF	CITATIONS
469	CT image standardization is superior to larger but heterogeneous data for robust radiomic models. Annals of Oncology, 2019, 30, ii20.	1.2	0
470	THU0345â€TEXTURE-BASED RADIOMICS FEATURES DISCRIMINATE DIFFERENT STAGES OF EXPERIMENTAL INTERSTITIAL LUNG DISEASE. , 2019, , .		0
471	IBS12.01 Questions to Be Addressed. Journal of Thoracic Oncology, 2019, 14, S102-S103.	1.1	Ο
472	1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial. Annals of Oncology, 2020, 31, S895-S896.	1.2	0
473	Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue. BMC Cancer, 2020, 20, 458.	2.6	0
474	Authors' Response to Letter to the Editor "Comments on â€~Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study'― Radiotherapy and Oncology, 2020, 145, 125-126.	0.6	0
475	MA06.06 Intracavitary Cisplatin-Fibrin followed by Irradiation after Lung Sparing Surgery in a Rat Model of Malignant Mesothelioma. Journal of Thoracic Oncology, 2021, 16, S153-S154.	1.1	Ο
476	Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Radiotherapy and Oncology, 2021, 164, 163-166.	0.6	0
477	Stereotaxic Body Radiotherapy for Stage I NSCLC. , 2015, , 33-48.		0
478	SU-F-R-51: Radiomics in CT Perfusion Maps of Head and Neck Cancer. Medical Physics, 2016, 43, 3384-3385.	3.0	0
479	Monitoring Patients in Ambulatory Palliative Care: A Design for an Observational Study. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2017, , 207-214.	0.3	0
480	Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials Journal of Clinical Oncology, 2018, 36, 8531-8531.	1.6	0
481	Radiation Therapy in Non-small-Cell Lung Cancer. , 2019, , 1-55.		0
482	Immobilization for SBRT: A Crucial Prerequisite Toward Accurate Treatment. , 2019, , 185-193.		0
483	SAT0569â€â€œIMAGES ARE MORE THAN PICTURES, THEY ARE DATA―[1] – EXPLORATION OF RADIOMICS / FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. Annals of the Rheumatic Diseases, 2020, 79, 1242.2-1243.	ANALYSIS 0.9	Ο
484	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL. Neuro-Oncology, 2020, 22, iii389-iii390.	1.2	0
485	Continuity and coordination of care in highly selected chronic cancer patients treated with multiple repeat radiation therapy. Radiation Oncology, 2021, 16, 227.	2.7	0
486	Stereotactic Irradiation of the Pancreas. Pancreas, 2022, 51, e62-e63.	1.1	0